{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2023,11,21]],"date-time":"2023-11-21T20:21:16Z","timestamp":1700598076641},"reference-count":44,"publisher":"Wiley","issue":"s6","license":[{"start":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T00:00:00Z","timestamp":1098144000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Aliment Pharmacol Ther"],"published-print":{"date-parts":[[2004,11]]},"abstract":"<jats:title>Summary<\/jats:title><jats:p>Control of gastric acid secretion by antisecretory agents has been the cornerstone of therapy in the successful management of all acid\u2010related disorders, including gastro\u2010oesophageal reflux disease (GERD), and duodenal and gastric ulcer. Treatment efficacy has been strongly correlated with degree and duration of acid suppression within the 24\u2010h period and with total duration of therapy. All proton pump inhibitors are highly effective for the healing of ulcers and erosive oesophagitis. All have closely similar mechanisms of action, yet important pharmacological differences exist, which can significantly impact certain aspects of their clinical efficacy. Rabeprazole's rapid activation over a wide pH range may be the explanation for its early onset of effective acid inhibition compared with other proton pump inhibitors such as omeprazole, lansoprazole and pantoprazole. Like rabeprazole, esomeprazole is also a potent inhibitor of gastric acid at steady state, although it is thought that rabeprazole may provide enhanced first\u2010day acid suppression compared with esomeprazole. First\u2010day antisecretory efficacy should produce faster symptom relief, a hypothesis supported by clinical data. Moreover, drugs with pharmacological profiles that include both rapid onset and potent antisecretory effects should help control healthcare costs by reducing the need for otherwise commonly used twice\u2010daily proton pump inhibitor administration.<\/jats:p>","DOI":"10.1111\/j.1365-2036.2004.02163.x","type":"journal-article","created":{"date-parts":[[2004,10,19]],"date-time":"2004-10-19T15:24:57Z","timestamp":1098199497000},"page":"30-37","source":"Crossref","is-referenced-by-count":19,"title":["Review article: pH, healing and symptom relief with rabeprazole treatment in acid\u2010related disorders"],"prefix":"10.1111","volume":"20","author":[{"given":"M.","family":"Robinson","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2004,10,19]]},"reference":[{"issue":"4","key":"e_1_2_8_2_2","first-page":"17S","article-title":"Optimizing the pharmacology of acid control in acid\u2010related disorders","volume":"92","author":"Howden CW","year":"1997","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_3_2","doi-asserted-by":"publisher","DOI":"10.1007\/BF02214870"},{"key":"e_1_2_8_4_2","first-page":"159","article-title":"pH, healing rate and symptom relief in acid\u2010related diseases","volume":"69","author":"Huang JQ","year":"1996","journal-title":"Yale J Biol Med"},{"key":"e_1_2_8_5_2","doi-asserted-by":"publisher","DOI":"10.1136\/gut.28.9.1120"},{"key":"e_1_2_8_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000200917"},{"key":"e_1_2_8_7_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(99)00658-9"},{"key":"e_1_2_8_8_2","first-page":"51B","article-title":"Efficacy of H2 receptor antagonists in the treatment of gastroesophageal reflux disease and its symptoms","volume":"11","author":"Tougas G","year":"1997","journal-title":"Can J Gastroenterol"},{"key":"e_1_2_8_9_2","doi-asserted-by":"publisher","DOI":"10.1002\/j.1875-9114.1997.tb03675.x"},{"issue":"1","key":"e_1_2_8_10_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1111\/j.1365-2036.1995.tb00778.x","article-title":"The role and limitations of H2\u2010receptor antagonists in the treatment of gastro\u2010oesophageal reflux disease","volume":"9","author":"Colin\u2010Jones DG","year":"1995","journal-title":"Aliment Pharmacol Ther"},{"key":"e_1_2_8_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.1994.tb00278.x"},{"key":"e_1_2_8_12_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2000.01701.x"},{"key":"e_1_2_8_13_2","doi-asserted-by":"publisher","DOI":"10.1097\/00042737-199610001-00002"},{"issue":"1","key":"e_1_2_8_14_2","first-page":"S43","article-title":"New\u2010generation proton pump inhibitors: overcoming the limitations of early\u2010generation agents","volume":"13","author":"Robinson M","year":"2001","journal-title":"Eur J Gastroenterol Hepatol"},{"key":"e_1_2_8_15_2","first-page":"A63","article-title":"Rabeprazole 20 mg compared with esomeprazole 40 mg in the control of intragastric pH in healthy volunteers","volume":"50","author":"Baisley KJ","year":"2002","journal-title":"Gut"},{"issue":"1","key":"e_1_2_8_16_2","first-page":"2","article-title":"Esomeprazole 40 mg provides more effective acid control than standard doses of all other proton\u2010pump inhibitors","volume":"120","author":"R\u00f6hss K","year":"2001","journal-title":"Gastroenterology"},{"key":"e_1_2_8_17_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2000.00788.x"},{"key":"e_1_2_8_18_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003495-199856030-00002"},{"key":"e_1_2_8_19_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(00)80032-6"},{"key":"e_1_2_8_20_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00019.x"},{"key":"e_1_2_8_21_2","doi-asserted-by":"publisher","DOI":"10.1074\/jbc.272.36.22438"},{"key":"e_1_2_8_22_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01573.x"},{"key":"e_1_2_8_23_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00418.x"},{"key":"e_1_2_8_24_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01496.x"},{"key":"e_1_2_8_25_2","first-page":"S48","article-title":"Rabeprazole 10\u2003mg is equivalent to esomeprazole 20\u2003mg in control of gastric pH in healthy volunteers","volume":"96","author":"Baisley KJ","year":"2001","journal-title":"Am J Gastroenterol"},{"key":"e_1_2_8_26_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(01)02876-3"},{"key":"e_1_2_8_27_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2002.01292.x"},{"key":"e_1_2_8_28_2","doi-asserted-by":"publisher","DOI":"10.2165\/00003088-200140070-00004"},{"key":"e_1_2_8_29_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01087.x"},{"key":"e_1_2_8_30_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1997.00244.x"},{"key":"e_1_2_8_31_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2003.08783.x"},{"key":"e_1_2_8_32_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2001.01030.x"},{"key":"e_1_2_8_33_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1021983611768"},{"key":"e_1_2_8_34_2","doi-asserted-by":"publisher","DOI":"10.1001\/archinte.159.7.649"},{"key":"e_1_2_8_35_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0149-2918(01)80087-4"},{"key":"e_1_2_8_36_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00438.x"},{"key":"e_1_2_8_37_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655200453566"},{"key":"e_1_2_8_38_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1999.00449.x"},{"key":"e_1_2_8_39_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.1998.00373.x"},{"key":"e_1_2_8_40_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1572-0241.2002.05532.x"},{"key":"e_1_2_8_41_2","doi-asserted-by":"publisher","DOI":"10.1023\/A:1005548318996"},{"key":"e_1_2_8_42_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2036.2003.01446.x"},{"key":"e_1_2_8_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/S0002-9270(02)04582-3"},{"key":"e_1_2_8_44_2","doi-asserted-by":"publisher","DOI":"10.1080\/003655298750027191"},{"key":"e_1_2_8_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2036.2004.02029.x"}],"container-title":["Alimentary Pharmacology &amp; Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02163.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1365-2036.2004.02163.x","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1365-2036.2004.02163.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T10:52:39Z","timestamp":1695811959000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1365-2036.2004.02163.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2004,10,19]]},"references-count":44,"journal-issue":{"issue":"s6","published-print":{"date-parts":[[2004,11]]}},"alternative-id":["10.1111\/j.1365-2036.2004.02163.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1365-2036.2004.02163.x","archive":["Portico"],"relation":{},"ISSN":["0269-2813","1365-2036"],"issn-type":[{"value":"0269-2813","type":"print"},{"value":"1365-2036","type":"electronic"}],"subject":[],"published":{"date-parts":[[2004,10,19]]}}}